WO2005002574A1 - Derives de pyrazolidinedione et leur utilisation en tant qu'inhibiteurs de l'agregation des plaquettes - Google Patents

Derives de pyrazolidinedione et leur utilisation en tant qu'inhibiteurs de l'agregation des plaquettes Download PDF

Info

Publication number
WO2005002574A1
WO2005002574A1 PCT/EP2003/006616 EP0306616W WO2005002574A1 WO 2005002574 A1 WO2005002574 A1 WO 2005002574A1 EP 0306616 W EP0306616 W EP 0306616W WO 2005002574 A1 WO2005002574 A1 WO 2005002574A1
Authority
WO
WIPO (PCT)
Prior art keywords
dione
pyrazolidine
phenyl
benzylidene
dimethyl
Prior art date
Application number
PCT/EP2003/006616
Other languages
English (en)
Inventor
Olivier Houille
Heinz Fretz
Kurt Hilpert
Markus Riederer
Thomas Giller
Olivier Valdenaire
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Priority to AU2003249865A priority Critical patent/AU2003249865A1/en
Priority to PCT/EP2003/006616 priority patent/WO2005002574A1/fr
Priority to US10/562,623 priority patent/US20070037846A1/en
Priority to PCT/EP2004/006471 priority patent/WO2005000281A2/fr
Priority to CA002529436A priority patent/CA2529436A1/fr
Priority to CNA2004800177171A priority patent/CN1812782A/zh
Priority to EP04739938A priority patent/EP1638540A2/fr
Priority to JP2006515947A priority patent/JP2007506661A/ja
Publication of WO2005002574A1 publication Critical patent/WO2005002574A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/62—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by hydrogenation of carbon-to-carbon double or triple bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/673—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
    • C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/542—Alkylated benzaldehydes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/548—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings having unsaturation outside the six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/56—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing hydroxy groups
    • C07C47/565—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing hydroxy groups all hydroxy groups bound to the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/575—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/28—Two oxygen or sulfur atoms
    • C07D231/30—Two oxygen or sulfur atoms attached in positions 3 and 5
    • C07D231/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Definitions

  • the present invention relates to alkylidene pyrazolidinedione derivatives which are effective platelet ADP receptor antagonists and can be used for the prevention and/or treatment of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals.
  • Hemostasis is referred to as the cooperation of complex, interrelated events maintaining the fluidity of the blood in the vascular system while allowing the rapid formation of a solid blood clot to prevent excessive blood loss (hemorrhage) subsequent to blood vessel injury.
  • a cascade of processes is initiated, such as contraction of the vessels, platelet adhesion and aggregation, activation of the coagulation cascade and later also of the fibrinolytic system.
  • Hemostasis is initiated by adhesion of blood platelets or thrombocytes to the exposed, highly thrombogenic, subendothelial connective tissue of the damaged vessels and aggregate to form a platelet plug to stop bleeding.
  • thrombosis can result in developing of an unwanted, in some instances life- threatening, intravascular thrombus.
  • Conditions such as turbulent blood flow in diseased vessels, disruption of underlying vessel wall, for example most commonly due to arteriosclerosis, exposure of damaged endothelial cells and release of mediators from circulating cells, activate platelet adhesion and aggregation resulting in arterial thrombus formation and hence block off arterial blood vessels causing serious disease.
  • Thrombi also form as a consequence of stasis or slow blood flow in veins. Venous thrombi can easily embolize, that means portions of them detach and travel through the circulatory system eventually blocking other vessels.
  • Venous thrombosis, thrombophlebitis, arterial embolism, coronary and cerebral arterial thrombosis, unstable angina, myocardial infarction, stroke, cerebral embolisms, kidney and pulmonary embolisms are serious conditions that are the common cause of death and disability in patients with vascular disease.
  • Initial stimuli such as thrombin, collagen, von Willebrand factor (vWf) , thromboxane A2 (TxA2) and ADP, activate platelets by binding to their respective cell surface receptors.
  • Many of these receptors belong to the family of seven transmembrane helices containing G-protein-coupled receptors, and their importance in platelet activation has been demonstrated (Offermans, S. et al . , Nature 1998, 389 (11) , 183-185) .
  • platelets change shape from a disc shape to a round form with pseudopodia, which enforces subsequent platelet adhesion and aggregation.
  • the final common event of aggregation culminates in cross- linking the platelets by binding of fibrinogen to its receptor, glycoprotein Ilb-IIIa (GPIIb-IIIa, integrin a nb P 3 ) receptor.
  • antiplatelet agents have been developed over the past several years (see review, Dogn ⁇ et al . , Curr. Med. Chem. 2002, 9(5), 577-589).
  • One of the first and so far most widely used agents in antiplatelet therapy is aspirin, which irreversibly inhibits the enzyme cyclooxygenase-1 and thereby affecting the TxA2 pathway.
  • aspirin is an agent that irreversibly inhibits the enzyme cyclooxygenase-1 and thereby affecting the TxA2 pathway.
  • treatment with aspirin remains the standard therapy against which new therapeutics are compared and judged.
  • the phosphodiesterase inhibitors dipyridamole and cilostazol have been introduced as antiplatelet agents.
  • GPIIb/IIIa antagonists like sibrafiban, xemilofiban, and orbofiban were under clinical evaluation but have not been successful so far-.
  • Indirect or direct thrombin inhibitors e.g. unfractionated heparin, low molecular weight heparins, hirudin, have also been shown to act as highly effective antithrombotic agents (Wong G.C. et al., JAMA 2003 Jan 15, 289(3), 331- 42; Antman E.M., Circulation 1994, 90, 1624- 1630, (GUSTO) Ha
  • Adenosine 5 ' -diphosphate was identified as a key mediator in platelet activation and aggregation acting on at least two platelet ADP receptors of the G-protein coupled P2 receptor family (Shaver S. R., Curr. Opin. Drug Dicovery & Development 2001, 4 (5), 665-670).
  • the P2Y. ⁇ receptor initiates aggregation through mobilization of calcium stores and is required for platelet shape change.
  • the more recently identified P2Y 12 receptor also denoted P2Y AT . P , P2Y AC , P2Y cyc , P 2T , P2T AC , (see review, Barnard E. A. and Simon J. , Trends Pharmacol. Sci.
  • analogues of the endogenous antagonist ATP for example AR-C (formerly FPL or ARL) 67085MX and AR-C69931MX (Cangrelor) , reached phase II clinical studies.
  • AR-C now FPL or ARL
  • 67085MX and AR-C69931MX (Cangrelor)
  • Cangrelor a selective platelet ADP receptor antagonists, which inhibit ADP-dependent platelet aggregation, and are effective in vivo (see review, Chattaraj S. C, Curr. Opin.
  • Boyer et al . disclose mononucleoside and dinucleoside polyphosphates as P2Y 12 receptor antagonists.
  • Bryant J. et al . disclose quinoline derivatives, useful as antithrombotic agents via inhibition of the platelet ADP receptor.
  • Bombrun A. et al . disclose the use of alkylidene pyrazolidinedione derivatives for the treatment and /or prevention of diabetes type I and/or II, impaired glucose tolerance, insulin resistance, hyperglycemia, obesity, and polycystic ovary syndrome via inhibition of phosphotyrosine phosphatases (PTPs) , in particular PTP1B, TC-PTP, SHP and GLEPP-1.
  • PTPs phosphotyrosine phosphatases
  • Hassan S. (Canadian patent application CA 2,012,634, published September 20, 1991) claims alkylidene pyrazolidinedione derivatives blocking platelet activating factor (PAF) and leukotriene D4 (LTD4) .
  • PAF platelet activating factor
  • LTD4 leukotriene D4
  • Krogdal T. G. discloses 3 , 5-pyrazolidinedione derivatives to combat viral infections.
  • the present invention relates to the use of pyrazolidinedione derivatives of the general formula
  • R x is hydrogen, optionally substituted alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl ; and R 2 is aryl or heteroaryl; tautomers thereof ; geometric isomers thereof and tautomers of these geometric isomers, including mixtures of individual compounds of formula (I), or tautomers thereof, and their geometric isomers, or tautomers thereof; pharmaceutically acceptable acid addition salts of compounds which are basic; pharmaceutically acceptable salts of compounds containing acidic groups with bases; pharmaceutically acceptable esters of compounds containing hydroxy or carboxy groups; prodrugs of compounds in which a prodrug forming group is present; as well as hydrates or solvates thereof; as platelet adenosine diphosphate receptor antagonists for the prevention and/or treatment of peripheral vascular, of visceral-, hepatic- and renal -vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombos
  • R j is preferably hydrogen, alkyl, aryl or heteroaryl, particularly hydrogen, alkyl, phenyl, bromophenyl, chlorophenyl , fluorophenyl, methylphenyl , methoxyphenyl , cyanophenyl , alkoxycarbonylphenyl or pyridinyl, more particularly hydrogen, methyl, phenyl, 2 -pyridinyl, 4-pyridinyl, 2- methylphenyl , 4-methylphenyl, 4-methoxyphenyl, 2- chlorophenyl , 4-fluorophenyl , 4-bromophenyl , 4-cyanophenyl or 4-ethoxycarbonylphenyl .
  • R 2 is preferably naphthalen-2-yl, thienyl or pyridyl, particularly naphthalen-2-yl, pyridin-3-yl or thiophen-3- yi-
  • R- L is as defined hereinabove;
  • R 3 is hydrogen, alkyl, alkenyl, alkynyl, alkoxy, hydroxyalkoxy, alkoxyalkoxy, alkenyloxy, cycloalkoxy or eyeloalkylalkoxy; and R 4 and R 5 , each independently of the other, are hydrogen, halogen, hydroxy, alkyl or alkoxy, or, together with the phenyl ring to which they are attached, form a fused, optionally substituted carbocyclic or heterocyclic ring system.
  • R 3 and R 5 in formula (III) each may be hydrogen and R 4 may be alkoxy, preferably methoxy; or R 3 and R 4 each may be hydrogen and R 5 may be alkoxy, preferably methoxy; or R 3 may be hydrogen, R 4 may be alkoxy, preferably methoxy, and R 5 may be hydroxy.
  • R 3 in formula (III) may be alkyl, alkenyl, alkynyl, alkoxy, cycloalkoxy, eyeloalkylalkoxy, hydroxyalkoxy or alkoxyalkoxy and R 4 and R 5 both may be hydrogen, or R 4 may be halogen, alkyl or alkoxy and R 5 may be hydrogen, or R 4 and R s each independently may be alkyl or alkoxy.
  • R 3 is preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, but-1-enyl, pent-1-enyl, but-1-ynyl, pent-1-ynyl, methoxy, ethoxy, propoxy, butoxy, isobutoxy, 3-methyl- butoxy, pentyloxy, cyclopentyloxy, hexyloxy, cyclopropylmethoxy, cyclobutylmethoxy, 2-hydroxy-ethoxy, 2- methoxy-ethoxy, and preferably R 4 and R 5 both are hydrogen or R 4 is chloro, bromo, methyl or methoxy and R 5 is hydrogen, or R 4 and R 5 each independently are methyl or methoxy.
  • R 3 in formula (III) may be hydrogen or alkoxy and R 4 and R 5 together with the phenyl ring to which they are attached, may form an optionally substituted naphthalene, tetrahydronaphthalene, indane, 1H- indene, dihydro-benzo [1,4] dioxine or benzo [1, 3] dioxole moiety.
  • R 3 is preferably propoxy and R 4 and R s together with the phenyl ring to which they are attached, preferably form a naphthalene-1-yl or 5,6,7,8- tetrahydronaphthalen-1-yl moiety.
  • the present invention thus relates to these novel compounds per se as well as for use as pharmaceutically active ingredients; to pharmaceutical compositions containing one or several of these novel compounds; to the use of these novel compounds as platelet adenosine diphosphate receptor antagonists for the prevention and/or treatment of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases and conditions associated with platelet aggregation, including thrombosis, and, respectively, for the manufacture of corresponding medicaments; and to the manufacture of these novel compounds .
  • novel compounds provided by the present invention are compounds of the general formula
  • R 3 is alkyl, alkenyl, alkynyl, alkoxy, hydroxyalkoxy, alkoxyalkoxy, alkenyloxy, cycloalkoxy or cycloalkylalkoxy; and R 4 and R 5 , each independently of the other, are halogen, hydroxy, alkyl or alkoxy, or, together with the phenyl ring to which they are attached, form a fused, optionally substituted carbocyclic or heterocyclic ring system, with the proviso that (i) if Ri is 4-iodophenyl and R 3 is hydroxy, R 4 and R s together with the phenyl ring to which they are attached may not be naphthalen-1-yl and
  • R t is phenyl and R 3 is methoxy
  • R 4 and R s may not both be methoxy.
  • R 3 may be alkyl, alkenyl, alkynyl, alkoxy, cycloalkoxy, cycloalkylalkoxy, hydroxyalkoxy or alkoxyalkoxy
  • R 4 may be halogen
  • alkyl or alkoxy may be alkyl or alkoxy.
  • R 3 is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, but-1-enyl, pent-1- enyl, but-1-ynyl, pent-1-ynyl, methoxy, ethoxy, propoxy, butoxy, isobutoxy, 3-methyl-butoxy, pentyloxy, cyclopentyloxy, hexyloxy, cyclopropylmethoxy, cyclobutylmethoxy, 2-hydroxy-ethoxy, 2-methoxy-ethoxy, R 4 is chloro, bromo, methyl or methoxy, and R s is methyl or methoxy.
  • R 3 may be alkoxy and R 4 and R 5 together with the phenyl ring to which they are attached, may form an optionally substituted naphthalene, tetrahydronaphthalene, indane, 1H- indene, dihydro-benzo [1, 4] dioxine or benzo [1, 3] dioxole ring system.
  • R 3 is propoxy and R 4 and R 5 together with the phenyl ring to which they are attached, form a naphthalene-1-yl or 5, 6, 7, 8-tetrahydronaphthalen-l-yl moiety.
  • Preferred novel compounds include 4- (4 -cyclopentyloxy-2, 3- dimethyl-benzylidene) -1-phenyl-pyrazolidine-3, 5-dione;
  • novel compounds include 4- (2,3- dimethyl-4-methoxybenzylidene) -1-phenyl-pyrazolidine-3, 5- dione;
  • Most preferred novel compounds include 4- (2, 3-dimethyl-4- propoxy-benzylidene) -1-phenyl-pyrazolidine-3, 5-dione; l-phenyl-4- (4-propoxy-5, 6, 7, 8-tetrahydro-naphthalen-l- ylmethylene) -pyrazolidine-3,5-dione;
  • the aforementioned novel compounds can be manufactured by condensing a pyrazolidinedione of the general formula (IV) , as shown in the following reaction scheme,
  • Some of the starting materials of the above general formulae (IV) and (V) are novel and also form part of the present invention.
  • These novel starting materials include the following pyrazolidinediones of the general formula (IV) : l-pyridin-2-yl-pyrazolidine-3, 5-dione; 1- (4-methoxy-phenyl) -pyrazolidine-3 , 5-dione; 4- (3, 5-dioxo-pyrazolidin-l-yl) -benzonitrile; 1- (2-methyl-phenyl) -pyrazolidine-3, 5-dione; and l-pyridin-4-yl-pyrazolidine-3 , 5-dione; and the following aldehydes of the general formula (V) 4-cyclopentyloxy-2, 3-dimethyl-benzaldehyde; 4-propoxy-5, 6,7, 8-tetrahydro-naphthalene-l- carbaldehyde;
  • alkyl refers to a saturated aliphatic group including a straight or branched hydrocarbon chain containing 1-8 carbon atoms.
  • Representative examples of alkyl include, but are not limited to, methyl, ethyl, n- propyl, iso-propyl, n-butyl, tert-butyl, iso-butyl (or 2- methylpropyl) , cyclopropylmethyl, n-pentyl, iso-pentyl, iso-amyl, n-amyl, n-hexyl, n-heptyl, n-octyl and the like.
  • the alkyl group can be optionally substituted with one or more substituents, each independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkylcarbonyl, alkylcarbonyloxy, alkylendioxy, alkylsulfinyl, alkylsulfonyl, alkylthio, alkynyl, amino, aminocarbonyl , aryl, arylalkenyl, arylalkyloxy, aryloxy, aryloxycarbonyl, arylsulfinyl, arylsulfonyl, arylthio, carboxy, cyano, formyl, halogen, haloalkoxy, heterocyclyl , hydroxy, mercapto, nitro, and the like, appended to any carbon atom of the alkyl moiety.
  • substituents each independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkylcarbonyl, alkylcarbon
  • lower alkyl refers to alkyl groups with 1-4 carbon atoms.
  • Representative examples of lower alkyl include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl and the like.
  • R a -R d refer to substituents, each individually and independently selected from hydrogen and alkyl, alkoxy, alkoxyalkyl and the like.
  • Representative examples of alkenyl include, but are not limited to, ethenyl, 2-propenyl, 2-methyl-2-propenyl, 3- butenyl, 4-pentenyl, 5-hexenyl and the like.
  • alkylenedioxy refers to a -0(CH 2 ) n O- group, wherein n is preferably 1 or 2 , and wherein the oxygen atoms are appended to two adjacent carbon atoms of the parent molecular moiety.
  • Representative examples of alkylenedioxy include, but are not limited to, methylenedioxy, ethylenedioxy, and the like.
  • alkynyl refers to a straight or branched hydrocarbon chain containing 2-8 carbon atoms with at least one carbon- carbon triple bond (R a -C ⁇ C-R b , R a and R b referring to substituents, each individually and independently selected from hydrogen and alkyl, alkenyl, alkoxy, alkoxyalkyl, and the like) .
  • Representative examples of alkynyl include, but are not limited to, acetylenyl, 1-propynyl, 2-propynyl, 1- butynyl, 3-butynyl, 2-pentynyl, and the like.
  • alkoxy refers to an alkyl group appended to the parent molecular moiety through an oxygen bridge .
  • Representative examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, 2-propoxy, butoxy, tert-butoxy, pentyloxy, hexyloxy, and the like.
  • alkoxyalkyl refers to an alkoxy group appended to the parent molecular moiety through an alkyl group.
  • Representative examples of alkoxyalkyl include, but are not limited to, tert-butoxymethyl, 2-ethoxyethyl, 2- methoxyethyl , methoxymethyl , and the like.
  • alkoxycarbonyl refers to an alkoxy group appended to the parent molecular moiety through a carbonyl group.
  • alkoxycarbonyl include, but are not limited to, methoxycarbonyl, ethoxycarbonyl, tert- butoxycarbonyl , and the like.
  • alkoxycarbonylalkyl refers to an alkoxycarbonyl group appended to the parent molecular moiety through an alkyl group.
  • alkoxycarbonylalkyl include, but are not limited to, methoxycarbonylpropyl , ethoxycarbonylbutyl, 2-tert-butoxycarbonylethyl, and the like.
  • alkylcarbonyl or "acyl”, as used herein, alone or in any combination, refers to an alkyl group appended to the parent molecular moiety through a carbonyl group.
  • alkylcarbonyl include, but are not limited to, acetyl, 1-oxopropyl, 2, 2-dimethyl-1- oxopropyl, 1-oxobutyl, 1-oxopentyl, and the like.
  • alkylcarbonylalkyl refers to an alkylcarbonyl group appended to the parent molecular moiety through an alkyl group.
  • Representative examples of alkylcarbonylalkyl include, but are not limited to, 2-oxopropyl, 3, 3-dimethyl-2-oxopropyl, 3-oxobutyl, 3-oxopentyl and the like.
  • alkylcarbonyloxy refers to an alkylcarbonyl group appended to the parent molecular moiety through an oxygen bridge.
  • Representative examples of alkylcarbonyloxy include, but are not limited to, acetyloxy, ethylcarbonyloxy, tert- butylcarbonyloxy and the like.
  • alkylsulfinyl refers to an alkyl group appended to the parent molecular moiety through a sulfinyl group.
  • Representative examples of alkylsulfinyl include, but are not limited to, methylsulfinyl, ethylsulfinyl and the like.
  • alkylsulfinylalkyl refers to an alkylsulfinyl group appended to the parent molecular moiety through an alkyl group.
  • Representative examples of alkylsulfinylalkyl include, but are not limited to, methylsulfinylmethyl, ethylsulfinylmethyl and the like.
  • alkylsulfonyl refers to an alkyl group appended to the parent molecular moiety through a sulfonyl group.
  • alkylsulfonyl include, but are not limited to, methylsulfonyl, ethylsulfonyl, and the like.
  • alkylsulfonylalkyl refers to an alkylsulfonyl group appended to the parent molecular moiety through an alkyl group.
  • alkylsulfonylalkyl include, but are not limited to, methylsulfonylmethyl, ethylsulfonylmethyl and the like.
  • alkylthio refers to an alkyl group appended to the parent molecular moiety through a thio group.
  • alkylthio include, but are not limited to, methylthio, ethylthio, tert-butylthio, hexylthio and the like.
  • alkylthioalkyl refers to an alkylthio group appended to the parent molecular moiety through an alkyl group.
  • alkylthioalkyl include, but are not limited to, methylthiomethyl, 2- (ethylthio) ethyl, and the like.
  • amino refers to a -NR e R f group, wherein R e and R f are substituents, each individually and independently selected from hydrogen, alkyl, aryl, arylalkyl, acyl, alkylcarbonyl, arylcarbonyl, carbamoyl, ureido, formyl, alkylsulfonyl, arylsulfonyl, and the like.
  • Representative examples of amino include, but are not limited to, dimethylamino, ethylamino, benzyl- (methyl) amino, and the like.
  • aminoalkyl refers to an amino group appended to the parent molecular moiety through an alkyl group.
  • aminoalkyl include, but are not limited to, aminomethyl, 2- (amino) ethyl, benzyl-
  • aminocarbonyl or “amido”, as used herein, alone or in any combination, refers to an amino group appended to the parent molecular moiety through a carbonyl group.
  • Representative examples of aminocarbonyl include, but are not limited to, dimethylaminocarbonyl , benzyl- aminocarbonyl, ethylaminocarbonyl , and the like.
  • aminocarbonylalkyl refers to an aminocarbonyl group appended to the parent molecular moiety through an alkyl group.
  • Representative examples of aminocarbonylalkyl include, but are not limited to, 2-amino-2-oxoethyl, 2- (benzylamino) -2- oxoethyl, 2- (methylamino) -2-oxoethyl, 4-amino-4-oxobutyl, 4- (dimethylamino) -4-oxobutyl, and the like.
  • aryl refers to an carbocyclic group having at least one aromatic ring, e.g. phenyl or biphenyl, or multiple condensed ring systems, in which at least one ring is aromatic, e.g. 1, 2, 3, 4-tetrahydronaphthyl, naphthyl , anthryl, phenanthryl, fluorenyl, and the like.
  • the aryl group may be optionally substituted with one or more functional groups individually and independently selected from alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonyl, alkylcarbonylalkyl, alkylcarbonyloxy, alkylendioxy, alkylsulfinyl, alkylsulfinylalkyl, alkylsulfonyl, alkylsulfonylalkyl, alkylthio, alkylthioalkyl, alkynyl, amino, aminoalkyl, aminocarbonyl, aminocarbonylalkyl, aryl, arylalkenyl, arylalkyloxy, arylalkyl, aryloxy, aryloxycarbonyl, aryloxycarbonylalkyl, arylsulfinylalkyl, arylsulfinylalkyl
  • arylalkenyl refers to an aryl group appended to the parent molecular moiety through an alkenyl group.
  • the aryl group may be unsubstituted or substituted.
  • Representative examples of arylalkenyl include, but are not limited to, 2- phenylethenyl, 3-phenylpropen-2-yl, 2-naphth-2-ylethenyl, and the like.
  • arylalkoxy refers to an aryl group appended to the parent molecular moiety through an alkoxy group.
  • the aryl group may be unsubstituted or substituted.
  • Representative examples of arylalkoxy include, but are not limited to, 2- phenylethoxy, 5-phenylpentyloxy, 3-naphth-2-ylpropoxy, and the like.
  • arylalkyl refers to an aryl group appended to the parent molecular moiety through an alkyl group.
  • the aryl group may be unsubstituted or substituted.
  • Representative examples of arylalkyl include, but are not limited to, benzyl, 2- phenylethyl, 3-phenylpropyl, 2-naphth-2-ylethyl, and the like.
  • aryloxy refers to an aryl group appended to the parent molecular moiety through an oxygen bridge .
  • the aryl group can be unsubstituted or substituted.
  • Representative examples of aryloxy include, but are not limited to, phenoxy, naphthyloxy, 3-bromophenoxy, 4-chlorophenoxy, 4- methylphenoxy, 3, 4-dimethoxyphenoxy, and the like.
  • R e and R f are substituents, each individually and independently selected from hydrogen, alkyl, arylalkyl, and the like.
  • thiocarbamoyl refers to a -C(S)NR e R £ group.
  • carbonyl as used herein, alone or in any combination, refers to a -C(O) group.
  • carboxyalkyl refers to a carboxy group appended to the parent molecular moiety through an alkyl group.
  • Representative examples of carboxyalkyl include, but are not limited to, carboxymethyl , 2-carboxyethyl, 3- carboxypropyl , and the like.
  • cyano refers to a -C ⁇ N group.
  • cyanoalkyl refers to a cyano group appended to the parent molecular moiety through an alkyl group.
  • Representative examples of cyanoalkyl include, but are not limited to, cyanomethyl, 2-cyanoethyl, 3-cyanopropyl, and the like.
  • cycloalkyl refers to a saturated cyclic hydrocarbon moiety containing 3-15 carbon atoms, optionally substituted with one or more groups, each individually and independently selected from alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonyl, alkylcarbonylalkyl, alkylcarbonyloxy, alkylendioxy, alkylsulfinyl, alkylsulfinylalkyl, alkylsulfonyl, alkylsulfonylalkyl, alkylthio, alkylthioalkyl, alkynyl, amino, aminoalkyl, aminocarbonyl, aminocarbonylalkyl, aryl, arylalkenyl, arylalkyloxy, arylalkyl, aryloxy, aryloxycarbonyl
  • cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and the like.
  • one of the distal rings may be aromatic, e.g., 1-indanyl, 2-indanyl, tetrahydronaphthalene, and the like.
  • cycloalkenyl and cycloalkynyl refer to unsaturated cyclic hydrocarbon moieties containing at least one carbon- carbon double or carbon-carbon triple bond, respectively. Such moieties may be optionally substituted with one or more groups as discussed hereinabove for the cycloalkyl groups .
  • formylalkyl refers to a formyl group, appended to the parent molecular moiety through an alkyl group.
  • formylalkyl include, but are not limited to, formylmethyl , 2-formylethyl, and the like.
  • halo or halogen, as used herein, alone or in any combination, refers to fluorine, bromine, chlorine, and iodine.
  • haloalkyl refers to an alkyl group having at least one hydrogen atom replaced with a halogen atom.
  • Representative examples of haloalkyl include, but are not limited to, chloromethyl , 2-fluoroethyl , trifluoromethyl , pentafluoroethyl , 2-chloro-3-fluoropentyl, and the like.
  • haloalkoxy refers to an alkoxy group having at least one hydrogen atom replaced with a halogen atom.
  • Representative examples of haloalkoxy include, but are not limited to, chloromethoxy, 2-fluoroethoxy, trifluoromethoxy, pentafluoroethoxy, and the like.
  • heterocyclyl refers to a monocyclic, bicyclic or polycyclic ring system containing up to 15 ring atoms, at least one of these being a hetero atom independently selected from nitrogen, oxygen or sulfur.
  • the ring system may be saturated, partially unsaturated, unsaturated or aromatic.
  • heterocyclyl include, but are not limited to, furyl, imidazolyl, imidazolinyl, imidazolidinyl, isothiazolyl, isoxazolyl, morpholinyl, oxadiazolyl, oxazolyl, oxazolinyl, oxazolidinyl, piperazinyl, piperidinyl, pyranyl, pyrazinyl, pyrazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrrolyl, pyrrrolinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrofuranyl , tetrahydrothienyl , thiadiazolyl, thiazolyl, thiazolinyl, thiazolidinyl, thienyl, thiomorpholinyl, 1,1- dioxothiomorpholinyl
  • heterocyclyl moieties may be optionally substituted with one or more groups, each individually and independently selected from alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonyl, alkylcarbonylalkyl, alkylcarbonyloxy, alkylendioxy, alkylsulfinyl, alkylsulfinylalkyl, alkylsulfonyl, alkylsulfonylalkyl, alkylthio, alkylthioalkyl, alkynyl, amino, aminoalkyl, aminocarbonyl, aminocarbonylalkyl, aryl, arylalkenyl, arylalkyloxy, arylalkyl, aryloxy, aryloxycarbonyl, aryloxycarbonylalkyl, arylsulfinylalkyl, arylsulfinyl
  • heteroaryl as used herein, alone or in any combination, is a special case of heterocyclyl and refers to a mono- or bicyclic or polycyclic aromatic ring system, in which at least one heterocyclic ring is aromatic.
  • heterocyclylalkenyl refers to a heterocyclyl group appended to the parent molecular moiety through an alkenyl group.
  • heterocyclylalkenyl include, but are not limited to, 2-pyrid-3-ylethenyl, 3-quinolin-3- ylpropen-2-yl, 5-pyrid-4-ylpenten-4-yl , and the like.
  • heterocyclylalkoxy refers to a heterocyclyl group appended to the parent molecular moiety through an alkoxy group.
  • Representative examples of heterocyclylalkoxy include, but are not limited to, 2-pyrid-3-ylethoxy, 3-quinolin-3- ylpropoxy, 5-pyrid-4-ylpentyloxy, and the like.
  • heterocyclylalkyl refers to a heterocyclyl group appended to the parent molecular moiety through an alkyl group.
  • heterocyclylalkyl include, but are not limited to, 2-pyrid-3-ylmethyl, 2-pyrimidin-2- ylpropyl, and the like.
  • heterocyclyloxy refers to a heterocyclyl group appended to the parent molecular moiety through an oxy group.
  • heterocyclyloxy include, but are not limited to, pyrid-3-yloxy, quinolin-3-yloxy, and the like.
  • hydroxy or "hydroxyl” as used herein, alone or in any combination, refers to an -OH group
  • hydroxyalkyl refers to an alkyl group having at least one hydrogen atom replaced with a hydroxy group.
  • Representative examples of hydroxyalkyl include, but are not limited to, hydroxymethyl, 2 -hydroxyethyl, 3-hydroxypropyl, 2-ethyl-4- hydroxyheptyl , and the like.
  • nitro refers to a -N0 2 group.
  • oxy refers to a -0- group.
  • Other compounds of this invention may contain one or more stereogenic or asymmetric centers, such as one or more asymmetric carbon atoms, and thus may give rise to optically pure enantiomers, mixtures of enantiomers, racemates, enantiomer-pure diastereomers, mixtures of diastereomers, epimers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)-, (S) - or (R,S) -configured, preferably in the (R) - or (S) -configuration.
  • Such isomers can be obtained by methods within the knowledge of one skilled in the art, e.g.
  • the present invention refers to compounds containing centers of any geometric asymmetry, like, for example, unsymmetrically substituted olefinic double bond, including E or Z geometric isomers and mixtures thereof. Generally, pure isomers of compounds of formulae (I) and (III) are preferred over isomeric mixtures.
  • the compounds of formulae (I) and (III) may be used in the form of pharmaceutically acceptable salts.
  • pharmaceutically acceptable salts refers to relatively nontoxic, inorganic or organic acid and base addition salts, which retain the biological effectiveness and properties of the parent compound, and which are not biologically or otherwise undesirable (see, e.g., Berge et al . , J. Pharm. Sci. 1977, 66, 1-19).
  • Certain compounds of the present invention can contain one or more basic functional groups, such as amino, alkylamino, or arylamino, and, thus, be capable of forming pharmaceutically acceptable acid addition salts.
  • These acid addition salts may be prepared by standard procedures in a suitable solvent from the parent compound of formula (Dor (III) , with an appropriate amount of an inorganic acid, including, but not limited to, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, or phosphoric acid; or of an organic acid, including, but not limited to, acetic acid, propionic acid, octanoic acid, decanoic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, ascorbic acid, amino acids, such as glutamic acid or aspartic acid, benzoic acid, cinnamic acid, salicylic acid, mandelic acid, methanesulf
  • Certain compounds of the present invention may, on the other hand, contain one or more acidic functional groups and, thus, be capable of forming pharmaceutically acceptable base addition salts.
  • These salts can be prepared by addition of an appropriate amount, usually in stoichiometric ratio, of an alkaline reagent, such as hydroxide, carbonate or alkoxide, containing the appropriate cation, to the free acid in a suitable solvent.
  • an alkaline reagent such as hydroxide, carbonate or alkoxide, containing the appropriate cation
  • Preferred inorganic salts include, but are not limited to, ammonium, sodium, potassium, calcium or magnesium, also zinc salts and the like.
  • Preferred salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines, cyclic amines, and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, lysine, arginine, N-ethylpiperidine, piperidine, polyamine resins, and the like.
  • basic ion exchange resins such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, lysine, arginine, N-ethylpiperidine, piperidine, polyamine resins, and the like.
  • salts for isolation or purification purposes, it is also possible to use pharmaceutically unacceptable salts, for example perchlorates, picolinates, picrates, or the like.
  • pharmaceutically acceptable salts or free compounds are employed, where applicable in the form of pharmaceutical preparations, and these are therefore preferred.
  • Certain compounds of formulae (I) and (III) may exist in solvated as well unsolvated forms, such as, for example, hydrated forms, or their crystals may, for example, include the solvent used for crystallization. Different crystalline forms may be present .
  • the present invention encompasses all such solvated and unsolvated forms.
  • prodrug derivatives of the parent compounds of formulae (I) and (III) .
  • prodrug refers to pharmacologically inactive precursors of a drug that may be converted into its therapeutically active form under physiological conditions in vivo, for example, when they undergo solvolysis, or enzymatic degradation in blood, or in cells, (Bundgard H., “Design of Prodrugs", pp. 7-9, 21-24, Elsevier, Amsterdam (1985); Silverman R. B., “The Organic Chemistry of Drug Design and Drug Action", pp. 352-401, Academic Press, San Diego, CA (1992); Higuchi T. et al . , "Pro-drug as Novel Delivery Systems", A.C.S.
  • prodrug also includes any covalently bonded carriers, which release the active parent compound in vivo when administered to a mammal.
  • Prodrug modifications of a compound often offer advantages of solubility, bioavailability, absorption, tissue compatibility, tissue distribution, or delayed release in the mammalian organism.
  • Prodrugs are variations or derivatives of the compounds of formulae (I) and (III) , which have groups cleavable under metabolic conditions, for example, pharmaceutically acceptable esters, or amides. Such groups can be cleaved enzymatically or non-enzymatically, or hydrolytically to the free hydroxy, carboxy, or amino group of the active parent compound.
  • the prodrug is a reduced form, which is oxidized in vivo to the therapeutic compound, for example, a thiol, which is oxidized to a sulfonate or sulfate, an alcohol to a carboxylic acid.
  • esters of the compounds of formulae (I) and (III) are pharmaceutically acceptable esters of the compounds of formulae (I) and (III) .
  • pharmaceutically acceptable esters refers to relatively non-toxic, esterified products of the parent compound. These esters can be prepared in si tu during the final isolation and purification of the compounds, or by separately reacting the purified compounds in its free acid or hydroxyl form with a suitable esterifying agent.
  • Carboxylic acids can be converted into esters via treatment with an alcohol in the presence of a catalyst .
  • Hydroxyl containing derivatives can be converted into esters via treatment with an esterifying agent such as alkanoyl halides.
  • the term further includes lower hydrocarbon groups capable of being solvated under physiological conditions, for example, alkyl esters, preferred methyl, ethyl, and propyl ester, methoxymethyl ester, methylthiomethyl ester, pivaloyloxymethyl ester and the like (see, e.g., Berge et al . , J. Pharm. Sci. 1977, 66, 1-19) .
  • the compounds of the present invention have useful, in particular pharmacologically useful, properties. They are able to specifically antagonize the effect of endogenous ADP on its platelet ADP receptor, the P2Y 12 receptor.
  • the platelet ADP receptor P2Y 12 upon activation with ADP is responsible for blood platelet aggregation.
  • the compounds of formulae (I) and (III) are therefore useful in treatment or prevention of vascular diseases that respond to the blockade of the P2Y 12 receptor.
  • a compound or a pharmaceutical composition of the invention may be used as a drug (medicine) or therapeutic agent for prevention and/ or treatment of peripheral vascular, cardiovascular and cerebrovascular diseases or conditions, associated with platelet aggregation, particularly related to thrombosis in humans and other mammals.
  • Such compounds may be useful as inhibitors of platelet activation, aggregation and degranulation, as anti-thrombotic agents or in the treatment and/or prevention of, for example any thrombosis, particularly platelet-dependent thrombotic indications, including, but not limited to, acute myocardial infarction, unstable angina, coronary angioplasty (PTCA) , perithrombolysis, primary arterial thrombotic complications of atherosclerosis such as thrombotic or embolic stroke, chronic stable angina, transient ischemic attacks, strokes, peripheral vascular disease, myocardial infarction with or without thrombolysis, pre-eclampsia/ eclampsia, venous thrombosis such as deep venous thrombosis, venoocclusive disease, embolism, disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, heparin-induced thrombocytopenia, hemolytic uremic syndrome, thro
  • the compounds of the invention may also be used for the prevention of mechanically-induced platelet activation in vivo, for example to prevent microthromboembolism in cardiopulmonary bypass; or in vi tro in the preservation of blood products, for example platelet concentrates; or shunt occlusion such as in renal dialysis and plasmapheresis, thrombosis secondary to vascular damage/ inflammation such as vasculitis, arteritis, glomerulonephritis, inflammatory bowel disease and organ graft rejection, conditions such as migraine, Raynaud's phenomenon, atheromatous plaque formation/progression, vascular stenosis/restenosis and asthma, in which platelet-derived factors play a role in the disease process.
  • the compounds of formulae (I) and (III) may be used as standard or reference compounds in tests or assays involving the inhibition of the platelet ADP receptor, P2Y 12 .
  • Such compounds could be made commercially available for use as a reference, quality standard or control, for example in pharmaceutical research when developing new assays or protocols related to P2Y 12 activity.
  • compounds of formulae (I) and (III) antagonize the ADP dependent activation of the platelet ADP receptor P2Y 12 .
  • the biological effect of such compounds may be tested in a variety of in vi tro, ex vivo and in vivo assays.
  • the ability of the compounds of formulae (I) and (III) to bind to the P2Y 12 receptor may be measured by methods similar to those described in Gachet C. et al . , Br. J. Hematol . 1995, 91, 434-444 and by the method described below in Example 15.
  • IC 50 values i.e. the concentrations where half-maximal inhibition of the interaction is found
  • test compounds of formulae (I) and (III) Exemplary IC S0 values determined in this test are given below in Example 16.
  • the ability of the compounds of the invention to inhibit ADP-induced aggregation of platelets may be measured by methods similar to those described in (Born, G.V.R., and M.J. Cross. 1963, J. Physiol., Vol. 168:178- 195) and the method described below in Example 17.
  • ED 50 i.e. the effective dose where half-maximal inhibition of the aggregation is found in the range of 0.05 to 5 ⁇ M, preferably values below 1 ⁇ M, in particular values below 0.1 ⁇ M, are found with test compounds of formulae (I) and (III) .
  • a functional assay with cells expressing the human P2Y 12 receptor may be used to detect changes in the levels of intracellular calcium concentration following compound treatment. After addition of the compound the cells are challenged with ADP. In a Fluorescent Imaging Plate Reader (FLIPRTM, Molecular Devices, Sunnyvale, California) fluorescence emission is recorded during both additions, emission peak values above base level after ADP addition were exported, normalized to low controls (no ADP) and high controls (no active compound) . The relative values of the remaining activity were used to determine IC 50 values by curve fitting them to a four-parameter logistic sigmoid curve .
  • FLIPRTM Fluorescent Imaging Plate Reader
  • IC 50 values i.e. the concentration of a compound at which the remaining activity is 50%
  • IC 50 values i.e. the concentration of a compound at which the remaining activity is 50%
  • a compound of formula (I) or (III) according to the invention may show therapeutic efficacy against vascular disorders mentioned herein, especially against thrombotic diseases.
  • a compound of formula (I) or (III) can be administered alone in pure form or in combination with one or more other therapeutic agents, possible combination therapy taking the form of fixed combinations or the administration of a compound of the invention and one or more other therapeutic agents being staggered or given independently of one another, or the combined administration of fixed combinations and one or more other therapeutic agents.
  • a compound of formula (I) or (III) can besides or in addition be administered especially for anti-thrombotic therapy in combination with other vascular diseases. Long- term therapy is equally possible as is adjuvant therapy in the context of other treatment strategies, as described above. Other possible treatments are preventive therapies, for example in patients at risk.
  • the invention relates also to pharmaceutical compositions comprising compounds of formula (III) , to their use in therapeutic, in a broader aspect of the invention also prophylactic treatment or a method of treatment of the diseases mentioned above, to the compounds for said use and to the preparation of pharmaceutical formulations (medicines) .
  • the pharmaceutically acceptable compounds of the present invention may be used, for example, for the preparation of pharmaceutical compositions that comprise an effective amount of the active ingredient together or in admixture with a significant amount of one or more inorganic, organic, solid or liquid, pharmaceutically acceptable carriers.
  • the invention relates also to a pharmaceutical composition that is suitable for administration to a warm-blooded animal, especially a human (or to cells or cell lines derived from a warm-blooded animal, especially a human, e.g. blood platelets), for the treatment or, in a broader aspect of the invention, prevention of (i.e. prophylaxis against) a disease that responds to blockade of the interaction of the platelet adenosine diphosphate (ADP) receptor with ADP, comprising an amount of a compound of formula (I) or (III) or a pharmaceutically acceptable salt or a prodrug thereof, which is effective for said inhibition, together with at least one pharmaceutically acceptable carrier.
  • ADP platelet adenosine diphosphate
  • compositions according to the invention are those for enteral administration, such as nasal, buccal, rectal, dermal or, especially oral administration, and for parenteral administration, such as intramuscular, intravenous or subcutaneous, intrasternal, intravitreal, injection or infusion, to warm-blooded animals, especially humans.
  • Such compositions comprise an effective dose of the pharmaceutically active ingredient, alone or together with a significant amount of a pharmaceutically acceptable carrier.
  • the dosage of the active ingredient depends on the species of warm-blooded animal, the body weight, the age and the individual conditions, individual pharmacokinetic data, the disease to be treated and the mode of administration.
  • the invention relates also to a process or a method for the treatment of a pathological condition mentioned hereinabove, especially a disease, which responds to blockade of the interaction of the platelet adenosine diphosphate (ADP) receptor with ADP, especially thrombosis.
  • ADP platelet adenosine diphosphate
  • the compounds of formulae (I) and (III) or salts or a prodrugs thereof can be administered as such or especially in the form of pharmaceutical compositions.
  • the dose to be administered to warm-blooded animals is preferably from approximatively 3 mg to approximatively 30 g, more preferably from approximatively 10 mg to approximatively 1000 mg per person per day, divided preferably into 1 to 3 single doses which may, for example, be of the same size.
  • the amount of the compound actually administered will typically be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, the weight, and response of the individual patient, the severity of the patient's symptoms, and the like, for example, children usually receive half of the adults dose.
  • compositions comprise from approximately 1% to approximately 95%, preferably from approximately 20% to approximately 90%, active ingredient.
  • Pharmaceutical compositions according to the invention may be, for example, in unit dosage forms such as coated and uncoated tablets, pills, ampoules, vials, suppositories, dragees, or capsules. Further dosage forms are, for example, ointments, creams, pastes, emulsions, foams, chewable gums, tinctures, lip-sticks, drops, sprays or aerosols, syrups or elixirs, dispersions, transdermal patches or pads, or via an intravitreal device that releases the compound in a sustained capacity, and the like. Examples are capsules containing from about 0.05 g to about 1.0 g active ingredient .
  • compositions of the present invention are prepared in a manner known, per se, for example by means of conventional mixing, granulating, coating, dissolving, lyophilizing or confectioning processes.
  • Solutions of the active ingredient, and also suspensions, and especially isotonic aqueous solutions or suspensions are preferably used, it being possible, for example in the case of lyophilized compositions, that comprise the active ingredient alone or together with a carrier, for example annitol, for such solutions or suspensions to be produced prior to use.
  • the pharmaceutical compositions may be sterilized and/or may comprise excipients, for example preservatives, stabilizers, wetting agents and/or emulsifiers, solubilizers, salts for regulating osmotic pressure and/or buffers and are prepared in a manner known per se, for example by means of conventional dissolving or lyophilizing processes.
  • the said solutions or suspensions may comprise viscosity-increasing substances, such as sodium carboxymethylcellulose, carboxymethylcellulose, dextran, polyvinylpyrrolidone or gelatin.
  • Suspensions in oil comprise as the oil component the vegetable, synthetic or semi-synthetic oils customary for injection purposes.
  • liquid fatty acid esters that contain as the acid component a long-chain fatty acid having from 8 to 22, especially from 12 to 22, carbon atoms, for example lauric acid, tridecylic acid, myristic acid, pentadecylic acid, palmitic acid, margaric acid, stearic acid, arachidic acid, behenic acid or corresponding unsaturated acids, for example oleic acid, elaidic acid, erucic acid, brasidic acid or linoleic acid, if desired with the addition of antioxidants, for example vitamin E, ⁇ -carotene or 3,5-di- tert-butyl-4-hydroxytoluene.
  • the alcohol component of those fatty acid esters has a maximum of 6 carbon atoms and is mono- or poly-hydroxy, for example a mono-, di- or trihydroxy, alcohol, for example methanol, ethanol, propanol, butanol, or pentanol or the isomers thereof, but especially glycol and glycerol.
  • fatty acid esters are therefore to be mentioned: ethyl oleate, isopropyl myristate, isopropyl palmitate, "Labrafil M2375” (polyoxyethylene glycerol trioleate, Gattefosse, Paris) , "Miglyol 812” (triglyceride of saturated fatty acids with chain length of C8 to C12, H ⁇ ls AG, Germany), but especially vegetable oils, such as cottonseed oil, almond oil, olive oil, castor oil, sesame oil, soybean oil and more especially groundnut oil.
  • vegetable oils such as cottonseed oil, almond oil, olive oil, castor oil, sesame oil, soybean oil and more especially groundnut oil.
  • compositions for oral administration can be obtained by combining the active ingredient with solid carriers, if desired granulating a resulting mixture, and processing the mixture, if desired or necessary, after the addition of appropriate excipients, into tablets, dragee cores or capsules. It is also possible for them to be incorporated into plastics carriers that allow the active ingredients to diffuse or be released in measured amounts.
  • Suitable carriers are especially fillers, such as sugars, for example lactose, saccharose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, for example tricalcium phosphate or calcium hydrogen phosphate, and binders, such as starch pastes using for example corn, wheat, rice, or potato starch, gelatin, tragacanth, methylcellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone, and/or, if desired, disintegrators, such as the above-mentioned starches, and/or carboxymethyl starch, crosslinked polyvinylpyrrolidone, agar, alginic acid or a salt thereof, such as sodium alginate.
  • fillers such as sugars, for example lactose, saccharose, mannitol or sorbitol
  • cellulose preparations and/or calcium phosphates for example tricalcium phosphate or calcium hydrogen phosphate
  • Excipients are especially flow conditioners and lubricants, for example silicic acid, talc, stearic acid or salts thereof, such as magnesium or calcium stearate, and/or polyethylene glycol.
  • Dragee cores are provided with suitable, optionally enteric, coatings, there being used, inter alia, concentrated sugar solutions which may comprise gum Arabic, talc, polyvinylpyrrolidone, polyethylene glycol, and/or titanium dioxide, or coating solutions in suitable organic solvents, or, for the preparation of enteric coatings, solutions of suitable cellulose preparations, such as ethylcellulose phthalate or hydroxypropylmethylcellulose phthalate.
  • Capsules are dry- filled capsules made of gelatin and of soft sealed capsules made of gelatine and a plasticiser, such as glycerol or sorbitol.
  • the dry-filled capsules may comprise the active ingredient in the form of granules, for example with fillers, such as lactose, binders, such as starches, and/or glidants, such as talc or magnesium stearate, and if desired with stabilizers.
  • the active ingredient is preferably dissolved or suspended in suitable oil excipients, such as fatty oils, paraffin oil or liquid polyethylene glycols, it being possible also for stabilizers and/or antibacterial agents to be added.
  • suitable oil excipients such as fatty oils, paraffin oil or liquid polyethylene glycols, it being possible also for stabilizers and/or antibacterial agents to be added.
  • Dyes or pigments may be added to the tablets or dragee coatings or the capsule casings, for example for identification purposes or to indicate different dose
  • aqueous solutions of an active ingredient in water-soluble form for example of a water-soluble salt, or aqueous injection suspensions that contain viscosity- increasing substances and stabilizers, are especially suitable.
  • the active ingredient optionally together with excipients, can also be in the form of a lyophilizate and be made into a solution before parenteral administration by the addition of solvents.
  • alkylidene pyrazolidinediones of formula (I) may be prepared by the condensation of pyrazolidinedione of formula (IV) with an aldehyde of formula (V) , optionally in the presence of a suitable base such as pyridine, piperidine, diisopropylethylamine, triethylamine, in a suitable solvent, such as ethanol, methanol, 1-butanol or acetic acid as shown in Scheme 1, hereinbelow.
  • the preferred conditions are heating the pyrazolidinedione of formula (IV) with an aldehyde of formula (V) in ethanol between 60 to 80°C.
  • Pyrazolidinediones of formula (IV) may be prepared as shown in Scheme 2, hereinbelow, by reacting an hydrazine of formula (VI) with a malonic derivative of formula (VII) whereby LG X and LG 2 could be any appropriate leaving groups such as halogen, or aliphatic or aromatic alkoxy groups.
  • a preferred method to prepare compounds of formula (IV) is the cyclization of compounds of formula (VIII) , by analogy with a method described by Michaelis A. and Burmeister R., Ber. 1892, 1502-1513, in the presence of an appropriate base such as sodium hydroxide, potassium hydroxide, sodium methoxide, sodium ethoxide, potassium carbonate, sodium hydride in a suitable solvent such as ethanol , methanol , tetrahydrofuran or N,N-dimethylformamide as shown in Scheme 3, hereinbelow.
  • the preferred conditions for the cyclization are stirring the compounds of formula (VI) at room temperature in ethanol in presence of sodium hydroxide .
  • compounds of formula (VIII) may be prepared by the condensation of hydrazines of formula (VI) with malonic acid derivatives of formula (VII) , whereby LG X is an appropriate leaving group such as OH, in the presence of a coupling reagent, such as 1, 3-dicyclohexylcarbodiimide, 0- (7-azabenzotriazol-l-yl) -N,N,N' ,N' -tetramethyluronium hexafluorophosphate, or whereby LG- ⁇ is any halogen in presence of a base such as triethylamine, N,N- diisopropylethylamine or pyridine in a suitable solvent such as tetrahydrofuran or N,N-dimethylformamide and LG 2 is an alkoxy or aryloxy group.
  • a coupling reagent such as 1, 3-dicyclohexylcarbodiimide, 0- (7-azabenzotriazol-l-y
  • Another preferred method to prepare compounds of formula (IV) is the condensation of hydrazines of formula (VI) with a dialkoxy malonate in a suitable solvent, like methanol or ethanol , in presence or absence of a base such as sodium methoxide or sodium ethoxide, by analogy with a method described by Conrad M. and Zart A., Ber. 1906, 2282-2288.
  • Aldehydes used in the Examples 1 and 2al2-2a28 were prepared as follows:
  • Example 5b 1- (4-Bromo-phenyl) -pyrazolidine-3, 5-dione used in Example 5a was prepared as follows:
  • Example 6b 1- (4-Methoxy-phenyl) -pyrazolidine-3 , 5-dione used in Example 6a was prepared as follows:
  • Example 7b 4- (3, 5-Dioxo-pyrazolidin-l-yl) -benzonitrile used in Example 7a was prepared as follows:
  • Example 8 is 4 -Fluorophenyl
  • Example 8b 1- (4-Fluoro-phenyl) -pyrazolidine-3, 5-dione used in Example 8a was prepared as follows:
  • Example 9b 1- (4-Methyl-phenyl) -pyrazolidine-3, 5-dione used in Example 9a was prepared as follows:
  • aqueous phase was then acidified to pH 1 by addition of IN aqueous HC1 and extracted with EtOAc (3 x 100 ml) .
  • the combined organic phases were washed with H 2 0 (50 ml) , brine (50 ml) , dried over MgS0 4 , filtered and concentrated.
  • CHO cells with recombinant expression of the human P2Y 12 receptor were cultured in 24 well cell-culture plates. Cells were washed three times with binding buffer (50 mM Tris pH 7.4, 100 mM NaCl, 1 mM EDTA, 0.5 %BSA) . The cells were then incubated with 0.5 ml per well binding buffer containing tritium-labeled 2- methyl-thio-adenosine 5 ⁇ -diphosphate (2-methyl-S-ADP) (between 100' 000 and 300 '000 dpm per well) and various concentrations of test compounds. After incubation at room temperature for 2 hours, cells were washed three times with binding buffer.
  • binding buffer 50 mM Tris pH 7.4, 100 mM NaCl, 1 mM EDTA, 0.5 %BSA
  • the cells were then incubated with 0.5 ml per well binding buffer containing tritium-labeled 2- methyl-thio-adenosine 5
  • Example 16 Test for antagonist binding to the platelet ADP receptor P2Y-.,.
  • Example 17 ADP induced Platelet Aggregation
  • Platelet aggregation was measured in a Chronolog lumiaggregometer with stirring (900 rpm) at 37°C. PRP was placed into the cuvette and allowed to equilibrate at 37°C for two min. In a first phase, the ADP concentration to give optimal extent of aggregation was determined for the PRP of each donor. In a second phase, PRP was incubated with inhibitors for 2 min at 37°C prior to the addition of the agonist ADP at 1-5 ⁇ M final concentration.
  • Chinese Hamster Ovary (CHO) cells stably expressing the human P2Y 12 receptor under the control of the cytomegalovirus promoter in the expression vector pcDNA3 (Invitrogen) were grown to near confluency in Ham's F-12 medium supplemented with 10% fetal calf serum (both Bioconcept, Switzerland) under standard mammalian cell culture conditions (37°C and 5% carbon dioxide) .
  • Cells were treated with 0.02% EDTA in phosphate buffer saline (PBS, Gibco) for 10 min, detached by tapping, and collected by centrifugation for five minutes at 200 g, all at room temperature.
  • PBS phosphate buffer saline
  • a FLIPR384 instrument (Molecular Devices) was operated following the manufacturer's standard instructions, adding 10 ⁇ l of compound dissolved at 10 mM in DMSO and diluted prior to the experiment in assay buffer to obtain the desired final concentration. 10 ⁇ l of ADP (Sigma) solution in assay buffer supplemented with bovine serum albumin (fatty acid content ⁇ 0.02%, Sigma) was then added to obtain a final concentration of 3 ⁇ M and 0.1%, respectively. Fluorescence emission was recorded during both additions.
  • a sterile-filtered aqueous solution, with 2% cyclodextrins as solubilisers, of one of the compounds of formula (III) mentioned in the preceding Examples (e.g. Example 8a) as active ingredient, is so mixed under aseptic conditions, with heating, with a sterile gelatin solution containing phenol as preservative, that 1.0 ml of solution has the following composition:
  • Example 20 Sterile dry substance for injection 5 mg of one of the compounds of formula (III) mentioned in the preceding Examples (e.g. Example 12alj as active ingredient are dissolved in 1 ml of an aqueous solution with 20 mg of mannitol and 20% cyclodextrins as solubilisers. The solution is sterile-filtered and introduced under aseptic conditions into a 2 ml ampoule, deep-frozen and lyophilized. Before use, the lyophilisate is dissolved in 1ml of distilled water or 1 ml of physiological saline solution. The solution is administered intramuscularly or intravenously. This formulation can also be introduced into a twin-chambered injection ampoule.
  • Example 12alj Sterile dry substance for injection 5 mg of one of the compounds of formula (III) mentioned in the preceding Examples (e.g. Example 12alj as active ingredient are dissolved in 1 ml of an aqueous solution with 20 mg of mannitol and 20% cyclodextrin
  • active ingredient 1000 g corn starch 680 g colloidal silica 200 g magnesium stearate 20 g stearic acid 50 g sodium carboxymethyl starch 250 g water quantum satis
  • a mixture of one of the compounds of formula (III) mentioned in the preceding Examples (e.g. Example 4a2) as active ingredient, 50 g of corn starch and the colloidal silica is processed with a starch paste, made from 250 g of corn starch and 2.2 kg of demineralised water, to form a moist mass. This is forced through a sieve having a mesh size of 3 mm and dried at 45°C for 30 min in a fluidized bed drier.
  • the dry granulates are pressed through a sieve having a mesh size of 1 mm, mixed with a pre-sieved mixture (l mm sieve) of 330 g of corn starch, the magnesium stearate, the stearic acid and the sodium carboxymethyl starch, and compressed to form slightly biconvex tablets.
  • a pre-sieved mixture l mm sieve
  • the pulverized active ingredient is suspenden in Lauroglykol ® (propylene glycol laureate, Glattefosse S. A., Saint Priest, France) and ground in a wet pulverizer to produce a particle size of about 1 to 3 ⁇ m. 0.42 g portions of the mixture are then introduced into soft gelatin capsules using a capsule-filling machine.
  • Lauroglykol ® propylene glycol laureate, Glattefosse S. A., Saint Priest, France

Abstract

L'invention concerne des dérivés de pyrazolidinedione de formule générale (I), dans laquelle R1 représente hydrogène, alkyle, cycloalkyle, aryle, arylalkyle, hétéroaryle ou hétéroarylalkyle facultativement substitué; et R2 représente aryle ou hétéroaryle; des tautomères de ceux-ci; des isomères géométrique de ceux-ci et des tautomères desdits isomères géométriques, notamment des mélanges de composés individuels de formule (I), ou des tautomères de ceux-ci, et leurs isomères géométriques, ou des tautomères de ceux-ci; des sels d'addition acides pharmaceutiquement acceptables de composés basiques; des sels pharmaceutiquement acceptables de composés contenant des groupes acides avec des bases ; des esters pharmaceutiquement acceptables de composés contenant des groupes hydroxy ou carboxy ; des promédicaments de composés contenant un groupe de formation de promédicament ; ainsi que des hydrates et solvates de ceux-ci. Les dérivés selon l'invention agissent en tant qu'antagonistes des récepteurs de l'adénosine diphosphate des plaquettes, et peuvent être utilisés dans la prévention et/ou le traitement des maladies vasculaires périphériques, de maladies viscérales-vasculaires, hépatiques-vasculaires, rénales-vasculaires, cardio-vasculaire et cérébro-vasculaires, ainsi que des affections liées à l'agrégation des plaquettes, en particulier la thrombose. Lesdits dérivés peuvent également être utilisés dans la fabrication des médicaments correspondants. Certains des composés de formule (I) sont de nouveaux composés.
PCT/EP2003/006616 2003-06-24 2003-06-24 Derives de pyrazolidinedione et leur utilisation en tant qu'inhibiteurs de l'agregation des plaquettes WO2005002574A1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AU2003249865A AU2003249865A1 (en) 2003-06-24 2003-06-24 Pyrazolidinedione derivatives and their use as platelet aggregation inhibitors
PCT/EP2003/006616 WO2005002574A1 (fr) 2003-06-24 2003-06-24 Derives de pyrazolidinedione et leur utilisation en tant qu'inhibiteurs de l'agregation des plaquettes
US10/562,623 US20070037846A1 (en) 2003-06-24 2004-06-16 Pyrazolidinedione derivatives
PCT/EP2004/006471 WO2005000281A2 (fr) 2003-06-24 2004-06-16 Derives de pyrazolidinedione
CA002529436A CA2529436A1 (fr) 2003-06-24 2004-06-16 Derives de pyrazolidinedione
CNA2004800177171A CN1812782A (zh) 2003-06-24 2004-06-16 吡唑烷二酮衍生物
EP04739938A EP1638540A2 (fr) 2003-06-24 2004-06-16 Dérivés de pyrazolidinedione et leur utilisation comme inhibiteurs d'agrégation plaquettaire
JP2006515947A JP2007506661A (ja) 2003-06-24 2004-06-16 ピラゾリジンジオン誘導体

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2003/006616 WO2005002574A1 (fr) 2003-06-24 2003-06-24 Derives de pyrazolidinedione et leur utilisation en tant qu'inhibiteurs de l'agregation des plaquettes

Publications (1)

Publication Number Publication Date
WO2005002574A1 true WO2005002574A1 (fr) 2005-01-13

Family

ID=33547562

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2003/006616 WO2005002574A1 (fr) 2003-06-24 2003-06-24 Derives de pyrazolidinedione et leur utilisation en tant qu'inhibiteurs de l'agregation des plaquettes
PCT/EP2004/006471 WO2005000281A2 (fr) 2003-06-24 2004-06-16 Derives de pyrazolidinedione

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/006471 WO2005000281A2 (fr) 2003-06-24 2004-06-16 Derives de pyrazolidinedione

Country Status (6)

Country Link
EP (1) EP1638540A2 (fr)
JP (1) JP2007506661A (fr)
CN (1) CN1812782A (fr)
AU (1) AU2003249865A1 (fr)
CA (1) CA2529436A1 (fr)
WO (2) WO2005002574A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009080227A2 (fr) 2007-12-26 2009-07-02 Sanofi-Aventis Dérivés de pyrazole-carboxamide utiles en tant qu'antagonistes de p2y12
US8426420B2 (en) 2007-12-26 2013-04-23 Sanofi Heterocyclic pyrazole-carboxamidesas P2Y12 antagonists

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070276011A1 (en) * 2003-09-11 2007-11-29 Susumu Muto Plasminogen Activator Inhibitor-1 Inhibitor
JPWO2007020935A1 (ja) * 2005-08-17 2009-02-26 小野薬品工業株式会社 Ｐ２ｙ１２受容体および／またはｐ２ｙ１４受容体ブロッカーを含有してなる疼痛治療剤
TWI391378B (zh) 2006-03-16 2013-04-01 Astellas Pharma Inc 喹啉酮衍生物或其製藥學上可被容許之鹽
WO2012157389A1 (fr) * 2011-05-16 2012-11-22 国立大学法人九州大学 Composé à faible poids moléculaire apte à réguler l'activation de rac induite par une molécule de la sous-famille de dock-a et utilisation associée
US10822357B2 (en) 2015-08-28 2020-11-03 Sekisui Medical Co., Ltd. Benzyl compound
WO2017131149A1 (fr) * 2016-01-29 2017-08-03 小野薬品工業株式会社 Dérivé de tétrahydronaphtalène
EP3595666A1 (fr) * 2017-03-15 2020-01-22 Idorsia Pharmaceuticals Ltd Administration sous-cutanée d'un antagoniste du récepteur p2y12
WO2019025426A1 (fr) 2017-07-31 2019-02-07 Horitzonts Tecnologics Hungary Korlátolt Felelosségu Társaság Composés permettant de traiter des infections

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2012634A1 (fr) * 1990-03-20 1991-09-20 Hassan Salari Tyrphostines pour le traitement des allergies et des affections inflammatoires et cardiovasculaires
WO2001009121A2 (fr) * 1999-07-30 2001-02-08 Basf Aktiengesellschaft 2-pyrazolin-5-ones
WO2002102359A2 (fr) * 2001-06-18 2002-12-27 Applied Research Systems Ars Holding N.V. Derives d'alkylidene pyrazolidinedione
WO2003074550A2 (fr) * 2002-03-01 2003-09-12 Pintex Pharmaceuticals, Inc. Composes de modulation de pin1 et procedes d'utilisation correspondant

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003002569A1 (fr) * 2001-06-29 2003-01-09 Novo Nordisk A/S Procede permettant d'inhiber ptp1b et / ou ptp de lymphocyte t et / ou d'autres ptpases a reste asp en position 48

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2012634A1 (fr) * 1990-03-20 1991-09-20 Hassan Salari Tyrphostines pour le traitement des allergies et des affections inflammatoires et cardiovasculaires
WO2001009121A2 (fr) * 1999-07-30 2001-02-08 Basf Aktiengesellschaft 2-pyrazolin-5-ones
WO2002102359A2 (fr) * 2001-06-18 2002-12-27 Applied Research Systems Ars Holding N.V. Derives d'alkylidene pyrazolidinedione
WO2003074550A2 (fr) * 2002-03-01 2003-09-12 Pintex Pharmaceuticals, Inc. Composes de modulation de pin1 et procedes d'utilisation correspondant

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002263366, Database accession no. 139:214344 (DN) *
DATABASE CROSSFIRE BEILSTEIN [online] Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; XP002263367, Database accession no. 3826996 (BRN) *
RECL. TRAV. CHIM. PAYS-BAS, (1924), 43, 853 *
SCIENCE OF SYNTHESIS (2002), 12, 15-225 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009080227A2 (fr) 2007-12-26 2009-07-02 Sanofi-Aventis Dérivés de pyrazole-carboxamide utiles en tant qu'antagonistes de p2y12
US8426420B2 (en) 2007-12-26 2013-04-23 Sanofi Heterocyclic pyrazole-carboxamidesas P2Y12 antagonists

Also Published As

Publication number Publication date
WO2005000281A2 (fr) 2005-01-06
AU2003249865A1 (en) 2005-01-21
CA2529436A1 (fr) 2005-01-16
EP1638540A2 (fr) 2006-03-29
JP2007506661A (ja) 2007-03-22
CN1812782A (zh) 2006-08-02
WO2005000281A3 (fr) 2005-04-14

Similar Documents

Publication Publication Date Title
KR102322794B1 (ko) 핵수송 조절인자 및 이의 용도
JP2923742B2 (ja) ４−アミノキナゾリン誘導体、その製造方法およびそれを含有する医薬品
CN103221404B (zh) 可用作pde10抑制剂的不饱和氮杂环化合物
US6387942B2 (en) Method of treating disorders related to protease-activated receptors-induced cell activation
JP3335362B2 (ja) キノレイン−２（１ｈ）−オン誘導体セロトニンアンタゴニスト
CN104822672A (zh) 治疗性化合物和组合物以及其作为pkm2调节剂的用途
CA2641345A1 (fr) Derives d'indazole pour le traitement de la maladie d'alzheimer
CA2287562A1 (fr) Inhibiteurs de la pde5 specifique de la gmpc a base de pyrazolopyrimidinone pour le traitement de la dysfonction sexuelle
TW201443046A (zh) 噻二唑類似物及治療ｓｍｎ缺乏相關症狀之方法
JPWO2005087749A1 (ja) ２−アミノキナゾリン誘導体
TW201919631A (zh) 丙酮酸激酶調節劑及其用途
WO2005002574A1 (fr) Derives de pyrazolidinedione et leur utilisation en tant qu'inhibiteurs de l'agregation des plaquettes
TW509682B (en) Phthalazine derivatives phosphodiesterase 4 inhibitors
CN104470363A (zh) 1,2,4-三嗪-6-甲酰胺激酶抑制剂
WO2017198178A1 (fr) Dérivé de thiazole et utilisations
RU2114845C1 (ru) Производные имидазопиридина или их фармацевтически приемлемые соли, способ их получения и фармацевтическая композиция, проявляющая антагонистическую активность в отношении гистамина (h1)
TWI468396B (zh) 環丙烷羧酸衍生物及其用途
JP2660016B2 (ja) 治療用薬剤
WO2012009137A1 (fr) Modulateurs de crth2
EP2549872B1 (fr) Antagonistes de trpv4
US20070037846A1 (en) Pyrazolidinedione derivatives
JP7102388B2 (ja) 単環式ヘテロアリール置換化合物
JP2002145883A (ja) ヒドロピリジン誘導体酸付加塩
WO2016063080A1 (fr) Dérivés d'indazole et d'indole en tant qu'inhibiteurs du récepteur orphelin gamma lié à l'acide rétinoïque (ror gamma) pour le traitement de maladies immunitaires
TW202220961A (zh) Ｐｈｄ抑制劑化合物、組成物及使用方法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP